Ainos Inc (AIMD) ニュース

As of March 7, 2025, there were issued and outstanding 15,433,257 shares of the registrant’s common stock, par value $0.01, which is the only class of common or voting stock of the registrant.

10K. weekend read. Pretty powerful news on this today
https://www.sec.gov/ix?doc=/Archives/edgar/data/1014763/000149315225009568/form10-k.htm

AIMD...59s clearing here....🥳

georgie18

Member Level
Re: georgie18 post# 672095

Thursday, January 23, 2025 12:38:56 PM

Post#
672148
of 676547
georgie18

Member Level
Re: georgie18 post# 388352

Thursday, January 23, 2025 9:28:06 AM

Post#
388939
of 388960
AIMD...70s adding here...🥳Loading under $1...

georgie18

Member Level
Re: georgie18 post# 670590

Friday, January 10, 2025 1:11:43 PM

Post#
671056
of 672094
AIMD...69...Hit $1 today...🥳

georgie18

Member Level
Re: georgie18 post# 388090

Monday, January 06, 2025 2:47:49 PM

Post#
388099
of 388351
AIMD...80s clearing here...🥳

georgie18

Member Level
Re: None

Monday, January 06, 2025 1:05:23 PM

Post#
670559
of 670589
AIMD...74s clearing here...🥳

Nice bit of news...thanks...🥳

sure: https://www.otcmarkets.com/stock/AIMD/news/story?e&id=3164503

Link please...🥳

nice news today

Lol...we vshall see...🥳

.73 Hidden treasure for those with patience $10 stock in future. Adds a dimension for robots ..smell and sniff then they can takeover a new world with 80% unemployment..lol

Moving up a bit...🥳holding...

.70 Eyes and ears ..head and toes from .60s looking good ..Patience pays once again 

$AIMD Key Highlights from the Report: AI Nose Programs and Strategic Milestones for 2025

AI Nose Technology: Ainos' Flagship Innovation

Robotics Integration: WTR noted that Ainos's strategic focus on positioning its AI Nose technology as a critical sensory enhancement for robotics and humanoid applications. The Company is actively seeking partnerships to integrate olfactory capabilities, addressing a pivotal gap in robot functionality.

Smart Manufacturing: In collaboration with Japanese partners, Ainos has developed a Volatile Organic Compounds ("VOC") sensing program with nearly 80% accuracy in identifying 22 VOCs across 761 test samples at semiconductor factories. WTR highlighted Ainos' plans for mass production by 1H2025, signaling significant potential in smart factory applications.

Elderly Care Monitoring: The report emphasizes Ainos' efforts to address Japan's aging population with an AI-driven telehealth system for long-term care facilities. The system monitors the elderly's hygiene and health by detecting VOCs linked to bowel movements and urine, with mass production also targeted for 1H2025. This program could facilitate the growing elderly care challenges in Japan's aging population. By 2040, Japan is projected to face a shortfall of approximately 570,000 caregivers, with a third of its population aged 65 and older.

Read more - https://finance.yahoo.com/news/water-tower-research-spotlights-ainos-150000620.html

I like what I am seeing.
https://finance.yahoo.com/news/ainos-achieves-major-breakthrough-japan-150000331.html

LOL...🥳...

Looks good $1.40s in the horizon I can smell it with that robot sensor

georgie18

Member Level
Re: georgie18 post# 388352

Thursday, January 23, 2025 9:28:06 AM

Post#
388939
of 388960
AIMD...70s adding here...🥳Loading under $1...

georgie18

Member Level
Re: georgie18 post# 670590

Friday, January 10, 2025 1:11:43 PM

Post#
671056
of 672094
AIMD...69...Hit $1 today...🥳

georgie18

Member Level
Re: georgie18 post# 388090

Monday, January 06, 2025 2:47:49 PM

Post#
388099
of 388351
AIMD...80s clearing here...🥳

georgie18

Member Level
Re: None

Monday, January 06, 2025 1:05:23 PM

Post#
670559
of 670589
AIMD...74s clearing here...🥳

AIMD...70s adding here...🥳Loading under $1...

georgie18

Member Level
Re: georgie18 post# 670590

Friday, January 10, 2025 1:11:43 PM

Post#
671056
of 672094
AIMD...69...Hit $1 today...🥳

georgie18

Member Level
Re: georgie18 post# 388090

Monday, January 06, 2025 2:47:49 PM

Post#
388099
of 388351
AIMD...80s clearing here...🥳

georgie18

Member Level
Re: None

Monday, January 06, 2025 1:05:23 PM

Post#
670559
of 670589
AIMD...74s clearing here...🥳

$AMPG Article : AmpliTech Group Inc. (AMPG): This Small-Cap Stock Is Poised To Outperform in 2025

https://finance.yahoo.com/news/amplitech-group-inc-ampg-small-142839733.html

News : Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule
https://finance.yahoo.com/news/ainos-granted-180-day-extension-140000423.html

$AIMD a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday environments."
https://finance.yahoo.com/news/ainos-unveils-ai-nose-robotics-150000016.html

$AIMD Key Benefits of Joining the Ainos Alliance:

Leverage Decades of Expertise: Collaborate with a proven leader in AI and sensory technology.

Secure First-Mover Advantage: Integrate AI Nose Technology into your products to capture market share.

Expand Applications: Unlock new possibilities in industrial safety, healthcare, and smart living.

Shape the Future Together: Collaborate on groundbreaking innovations that redefine the capabilities of robots.

"Originated from healthcare use-case, our AI Nose technology represents nearly a decade of innovation and perseverance," said Chun-Hsien (Eddy) Tsai, CEO of Ainos. "With the robotics and humanoid markets experiencing unprecedented growth, this is the moment to act. Partnering with us now means joining a team with a proven track record of success and ensuring your company's position at the forefront of the industry."

To join the Ainos Alliance or learn more about AI Nose, contact us today:

Media and Partnership: info@ainos.com
Investor relation: ir@ainos.com
Website: www.ainos.com

$AIMD AI Nose is a Game-Changer, Elevating Robot's Interaction with Our World

1. Transforming Home Safety

Detects gas leaks, burning odors, and other safety hazards, sending immediate alerts to prevent accidents.

Enhances smart home environments by proactively addressing unpleasant odors, such as those from kitchen waste.

2. Revolutionizing Healthcare

Enables non-invasive early detection of diseases by analyzing volatile organic compounds (VOCs) emitted by you.

Provides real-time health monitoring for chronic disease patients, offering smarter healthcare solutions.

https://finance.yahoo.com/news/ainos-unveils-ai-nose-robotics-150000016.html

AIMD...69...Hit $1 today...🥳

georgie18

Member Level
Re: georgie18 post# 388090

Monday, January 06, 2025 2:47:49 PM

Post#
388099
of 388351
AIMD...80s clearing here...🥳

georgie18

Member Level
Re: None

Monday, January 06, 2025 1:05:23 PM

Post#
670559
of 670589
AIMD...74s clearing here...🥳

AIMD BLOWING UP

AIMD...80s clearing here...🥳

georgie18

Member Level
Re: None

Monday, January 06, 2025 1:05:23 PM

Post#
670559
of 670589
AIMD...74s clearing here...🥳

AIMD...74s clearing here...🥳

$AIMD Podcast - Veldona's therapeutic potential and ongoing clinical trials in Taiwan, covering HIV+ oral warts, Sjogren’s syndrome & cat FCGS.
https://drive.google.com/file/d/101N4WNjst-4MEmWe3E_oyCGQiHvbSHDw/view?usp=sharing

$AIMD Podcast - Veldona's therapeutic potential and ongoing clinical trials in Taiwan, covering HIV+ oral warts, Sjogren’s syndrome & cat FCGS.
https://drive.google.com/file/d/101N4WNjst-4MEmWe3E_oyCGQiHvbSHDw/view?usp=sharing

$AIDM 🔥 Must-Listen Alert! 🔥 Dive into research with @WTR_Research! 🎙️ This podcast discuss #Veldona's therapeutic potential and ongoing clinical trials in Taiwan, covering HIV+ oral warts, #Sjogren’s Syndrome, and cat FCGS. Don't miss out!
⏳ #AinosInc $AIMD $AIMDW #nasdaq #biotech #Podcast #Research #ListenNow #Sjogren’sSyndrome #Veldona #RareDisease #OrphanDrug https://x.com/WTR_Research/status/1849078364016930937

$AIMD Podcast out, #PharmaPartnerships #DrugOutlicensing #PharmaDeals #SjogrensSyndrome #AutoimmuneDisease #OrphanDrug #RareDisease #ClinicalTrial #AinosInc #AIMD $AIMD #MitsubishiTanabePharma
https://drive.google.com/file/d/1NfmvbVQCrsb6w0ttKZptoQPv_HPKZemL/view?usp=sharing


$AIMD - 1. 🚀 Big news! Ainos, Inc. is partnering with Taiwan Tanabe Seiyaku to introduce VELDONA®️ in Taiwan for Sjögren's syndrome. This condition, affecting 1% globally, causes dry eyes and mouth, with current treatments only managing symptoms. Read more: https://www.newsfilecorp.com/release/231739/Ainos-Inc.-Announces-Strategic-Partnership-with-Taiwan-Tanabe-Seiyaku-to-Advance-Manufacturing-and-Taiwan-Market-Promotion-of-Sjgrens-Syndrome-Drug #AinosInc $AIMD #AIMD #Veldona #Biotechnology #AutoimmuneDisease #ClinicalTrial #DrugOutlicensing #OrphanDrug #PharmaDeals #PharmaPartnerships #RareDisease #SjogrensSyndrome
2. 🌟 Major milestone! The MOU between Ainos and Taiwan Tanabe Seiyaku kickstarts Ainos' Veldona outlicensing strategy. This partnership aims to accelerate the market entry of innovative treatments. Read more: https://www.newsfilecorp.com/release/231739/Ainos-Inc.-Announces-Strategic-Partnership-with-Taiwan-Tanabe-Seiyaku-to-Advance-Manufacturing-and-Taiwan-Market-Promotion-of-Sjgrens-Syndrome-Drug #AinosInc $AIMD #AIMD #Veldona #Biotechnology #AutoimmuneDisease #ClinicalTrial #DrugOutlicensing #OrphanDrug #PharmaDeals #PharmaPartnerships #RareDisease #SjogrensSyndrome
3. 🌍 Promising results! Ainos' VELDONA®️ is showing great potential in clinical trials for Sjögren's syndrome, a condition affecting 1% globally with no curative therapy. Read more: https://www.newsfilecorp.com/release/231739/Ainos-Inc.-Announces-Strategic-Partnership-with-Taiwan-Tanabe-Seiyaku-to-Advance-Manufacturing-and-Taiwan-Market-Promotion-of-Sjgrens-Syndrome-Drug #AinosInc $AIMD #AIMD #Veldona #Biotechnology #AutoimmuneDisease #ClinicalTrial #RareDisease #SjogrensSyndrome

$AIMD News - Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing #AinosInc $AIMD #AIMD #Veldona #Biotechnology #AutoimmuneDisease #ClinicalTrial #RareDisease #SjogrensSyndrome
https://www.otcmarkets.com/stock/AIMD/news/story?e&id=3065363

MOU Highlights
1. 🌟 Ainos and Taiwan Tanabe Seiyaku have signed an MOU to advance the manufacturing and Taiwan market promotion of VELDONA®️ for Sjögren’s syndrome. This international cooperation addresses the unmet need for effective treatments and leverages clinical benefits from prior Phase 3 studies. Taiwan Tanabe Seiyaku, a subsidiary of Mitsubishi Tanabe Pharma in Japan, excels in Taiwan and neighboring markets with specialty therapeutics for autoimmune diseases, diabetes, and other major health conditions. #PharmaPartnerships #DrugOutlicensing #PharmaDeals #SjogrensSyndrome #AutoimmuneDisease #OrphanDrug #RareDisease #ClinicalTrial #AinosInc #AIMD $AIMD #MitsubishiTanabePharma

🚀 Exciting Update! 🚀 Ainos has signed an MOU with Taiwan Tanabe Seiyaku Co., Ltd. to advance the production and marketing of Sjögren's syndrome drug, VELDONA, in Taiwan. This international partnership taps into Taiwan Tanabe's strong pharmaceutical expertise and market presence.

New $AIMD Podcast out-
https://drive.google.com/file/d/1sCdlpGCZQSGNObKvzCPsILQtaY9-HmbS/view?usp=sharing

$AIMD News out- Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug
https://www.otcmarkets.com/stock/AIMD/news/story?e&id=3062502

Listen to @WTR_Research podcast with @AinosInc to get insight on Veldona's therapeutic potential and ongoing clinical trials in Taiwan, covering HIV+ oral warts, Sjogren’s syndrome & cat FCGS. A lot to look forward to in 2025!

$AIMD #Veldona #AinosInc

Apple:https://podcasts.apple.com/podcast/id1693448305
Spotify:https://open.spotify.com/show/65HhA2UPZVDW55kA3sCkXh

mix it with reposts of https://x.com/WTR_Research/status/1849078364016930937

Recent podcast, very interesting. 

https://drive.google.com/file/d/1QZCY2SUUD0e7vBbdZMx3CioQynqqCJvu/view?usp=drivesdk

maybe some potential on the long here

$AIMD Tune in to WTR Small-Cap Spotlight with WTR's Do Kim and Jack Lu from
@AinosInc
on Veldona's therapeutic potential and ongoing clinical trials in Taiwan, covering HIV+ oral warts, Sjogren’s syndrome & cat FCGS
https://x.com/WTR_Research/status/1849078364016930937

There is no cure for Sjogren’s Syndrome, only symptom management. Ainos previous clinical trials show Veldona may improve oral dryness without serious side effects. There is hope for patients

 Sjogren’s syndrome an affect the entire body! In addition to severe dryness, complications can include extreme fatigue, chronic pain, and organ issues. It’s a complex disease!

$AIMD - AINOS Inc.
🔹Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments
🔹Taiwan regulatory approval for the trial expected in Q1 2025
🔹Remains committed to a capital-efficient business strategy
🔹Low Float/ OS near 7.6m shares

$AIMD - Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products.
http://www.ainos.com/

Water Tower Research just highlighted the IRB approval for the VELDONA® clinical trial for primary Sjogren's syndrome. This trial, starting in April 2025, could revolutionize treatment for this condition with no approved therapies. https://feeds.issuerdirect.com/news-release.html?newsid=7518957985987465

Exciting news! 🎆 Ainos has received IRB approval for its Sjögren’s Syndrome clinical study at Shuang Ho Hospital, Taipei Medical University! 🌟 Next step: regulatory approvals in Q1 2025. VELDONA has shown promising results in Phase 3 studies. https://feeds.issuerdirect.com/news-release.html?newsid=7333369263066478

Ainos, Inc. is enhancing its patent portfolio with 28 new patents for AI Nose and a groundbreaking nitrogen-oxygen separation technology. This innovation extracts nitrogen and oxygen from air with over 99% purity, using only a third of the energy of traditional methods, revolutionizing energy-efficient medical oxygen supply. https://www.accesswire.com/935576/ainos-expands-patent-portfolio-with-strategic-shareholders-cutting-edge-technology-assets

WTR has just released a recap note on yesterday's Small-Cap Spotlight podcast featuring #AIMD.
https://feeds.issuerdirect.com/news-release.html?newsid=4786114891531438
Here are the key highlights:

Safe, Oral Low-Dose Interferon-a ("IFN-a") Therapeutic
Extensive Clinical History
Rare Disease Focus
Animal Health Potential
Milestones for the Next 18 Months
Don't miss out! If you don't have access to the WTR website, head over to Ainos' IR website under the news section to get all the details. 📈✨

#SmallCapSpotlight #AIMD #Biotech #InvestmentNews #AinosIR #WTRRecap

$AIMD EMA ANALYSIS

$AIMD News Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies https://finance.yahoo.com/news/ainos-advances-healthcare-industrial-innovations-120000322.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr

🚨 Let's recap Ainos VELDONA for better pet and human health! Dive into WTR report to discover how #VELDONA is positioned to revolutionize treatments for cat gum disease, #HIV oral warts, and #Sjogren’s syndrome. 🐱💊 #AinosInc $AIMD #AIMD Read more: https://irp.cdn-website.com/7a7a7e3d/files/uploaded/Water_Tower_Research_Management_Series_Report_-_August_26-_2024.pdf